CN112999200B - Transdermal drug delivery layer - Google Patents
Transdermal drug delivery layer Download PDFInfo
- Publication number
- CN112999200B CN112999200B CN202110234195.6A CN202110234195A CN112999200B CN 112999200 B CN112999200 B CN 112999200B CN 202110234195 A CN202110234195 A CN 202110234195A CN 112999200 B CN112999200 B CN 112999200B
- Authority
- CN
- China
- Prior art keywords
- parts
- layer
- medicine
- drug delivery
- slow release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000013271 transdermal drug delivery Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 76
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 43
- 238000010438 heat treatment Methods 0.000 claims abstract description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 30
- 239000003792 electrolyte Substances 0.000 claims abstract description 27
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims abstract description 26
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims abstract description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims abstract description 26
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 26
- 229920000098 polyolefin Polymers 0.000 claims abstract description 21
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 239000005543 nano-size silicon particle Substances 0.000 claims description 20
- 235000012239 silicon dioxide Nutrition 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 11
- 238000012377 drug delivery Methods 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 235000011201 Ginkgo Nutrition 0.000 claims description 4
- 241000218628 Ginkgo Species 0.000 claims description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 24
- 230000007704 transition Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 239000000377 silicon dioxide Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 7
- 238000005299 abrasion Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005338 heat storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-NJFSPNSNSA-N silicon-30 atom Chemical group [30Si] XUIMIQQOPSSXEZ-NJFSPNSNSA-N 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/368—General characteristics of the apparatus related to heating or cooling by electromagnetic radiation, e.g. IR waves
Abstract
A transdermal drug delivery layer comprising, in order: a heating layer and a slow release layer; the heating layer is used for promoting the slow release layer to slowly release the slow release medicine in a heating state, and the heating temperature is 40-60 ℃; the slow-release layer is attached to the affected part of the skin; the slow release medicine comprises: the heat transfer component and the effective component are in a ratio of (0.1-10) in mass percent: 1, a step of; the heat transfer component comprises: graphene, nano-silica, and polyolefin; the effective components comprise: liposomes, cholesterol, electrolytes, and drugs; the phase transition temperature of the liposome is 40-60 ℃; the liposome comprises: distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine. The transdermal drug delivery layer can be used for diminishing inflammation on the affected part of the skin, and the effective components of the slow release layer are heated by the heating layer, so that electrolytes and medicines in the effective components are slowly released to the surface of the skin, and the effect of curing the affected part of the skin by the slow release medicines is realized.
Description
Technical Field
The invention relates to the technical field of drug delivery devices, in particular to a percutaneous drug delivery layer.
Background
When the body is accidentally scratched during exercise, the scratch is presented as blood mark, epidermis peeling, bleeding or bleeding spot, and inflammatory reaction can occur, and local red swelling and pain can occur; the existing mild abrasion is mainly repaired by the body autonomously, and the wound can be healed in 3 days; however, in the case of severe abrasion, gauze is mainly used for wrapping, but the treatment mode has no promotion effect on inflammatory diseases and is still used for treating the inflammatory diseases through the healing function of the body.
Disclosure of Invention
The invention aims to provide a percutaneous drug delivery layer, which is characterized in that a heat transfer component with graphene, nano silicon dioxide and polyolefin is combined with a slow release drug formed by the graphene, the nano silicon dioxide and the polyolefin, and infrared radiation is received on the slow release layer, so that the slow release drug of the slow release layer slowly releases an effective component on the surface of the skin.
To achieve the purpose, the invention adopts the following technical scheme:
a transdermal drug delivery layer comprising, in order: a heating layer and a slow release layer;
the heating layer has a heating function and is used for promoting the slow release layer to slowly release the slow release medicine in a heating state, and the heating temperature is 40-60 ℃; the slow release layer is attached to the affected part of the skin;
the slow release medicine comprises: the heat transfer component and the effective component are in a ratio of (0.1-10) in percentage by mass: 1, a step of;
the heat transfer component comprises: graphene, nano-silica, and polyolefin;
the effective components comprise: liposomes, and cholesterol, electrolytes and drugs in the liposomes, respectively; the phase transition temperature of the liposome is 40-60 ℃, and the liposome is subjected to membrane stripping at the phase transition temperature, so that the medicine is released outside the membrane; the liposome comprises: distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine.
Preferably, the effective components comprise the following components in parts by mass: 20-30 parts of liposome, 1-5 parts of cholesterol, 20-25 parts of electrolyte and 20-25 parts of medicine.
Preferably, the distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine are in a mass ratio of (1-3): 1.
Preferably, the heat transfer component further comprises: polyvinyl alcohol and polyvinylpyrrolidone.
More preferably, the heat transfer component comprises the following components in parts by mass: 15-25 parts of polyolefin, 30-45 parts of nano silicon dioxide, 30-45 parts of graphene, 8-10 parts of polyvinyl alcohol and 15-19 parts of polyvinylpyrrolidone.
Preferably, the heat transfer component comprises the following components in parts by mass: 30-45 parts of graphene, 30-45 parts of nano silicon dioxide and 15-25 parts of polyolefin.
Preferably, the heating layer is fitted with an infrared device with adjustable intensity.
Preferably, the heating layer is provided with a transparent medicament tank; the irradiation end of the infrared device irradiates towards the medicine tank.
Preferably, the irradiation ends of the infrared device are plural and arranged in sequence, and the irradiation ends intermittently irradiate the slow release layer.
The invention has the beneficial effects that:
the transdermal drug delivery layer can be used for diminishing inflammation on the affected part of the skin, and the effective components of the slow release layer are heated by the heating layer, so that electrolytes and medicines in the effective components are slowly released to the surface of the skin, the medicine is slowly released on the skin for a long time, and the affected part of the skin is cured by the medicine.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments.
A transdermal drug delivery layer comprising, in order: a heating layer and a slow release layer;
the heating layer has a heating function and is used for promoting the slow release layer to slowly release the slow release medicine in a heating state, and the heating temperature is 40-60 ℃; the slow release layer is attached to the affected part of the skin;
the slow release medicine comprises: the heat transfer component and the effective component are in a ratio of (0.1-10) in percentage by mass: 1, a step of;
the heat transfer component comprises: graphene, nano-silica, and polyolefin;
the effective components comprise: liposomes, and cholesterol, electrolytes and drugs in the liposomes, respectively; the phase transition temperature of the liposome is 40-60 ℃, and the liposome is subjected to membrane stripping at the phase transition temperature, so that the medicine is released outside the membrane; the liposome comprises: distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine.
The transdermal drug delivery layer can be used for diminishing inflammation on the affected part of the skin, and the effective components of the slow release layer are heated by the heating layer, so that electrolytes and medicines in the effective components are slowly released to the surface of the skin, the medicine is slowly released on the skin for a long time, and the affected part of the skin is cured by the medicine.
The heating layer is a non-drug application layer, and can be a carrier of the slow release layer or arranged at intervals from the slow release layer; when the slow-release layer is coated on the affected part of the skin, only the heating function of the heating layer is started, and infrared rays from the heating layer can irradiate on the slow-release layer; the slow release layer adopts graphene, nano silicon dioxide and polyolefin, and the heat conduction performance of the graphene, the nano silicon dioxide and the polyolefin is gradually and sequentially reduced, and the effective components can be mixed with the heat transfer components, so that the temperature of the effective components can be controlled only by controlling the proportion of the graphene, the nano silicon dioxide and the polyolefin; meanwhile, the overall granularity of the graphene, the nano silicon dioxide and the polyolefin in the heat transfer component is larger than that of the active component, so that the overall volume of the buffer medicine can be increased, the heat transfer area of the heat transfer component is large, the interaction between distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine and lipid layers of skin horny layers can be promoted to be disintegrated, the horny lipid structure can be changed, and the barrier of horny substances can be further reduced, so that the electrolyte and the medicine act on affected parts of the skin; and the affected part of the skin is easier to absorb the medicine due to the decrease of the barrier degree.
Distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine are liposomes which release the drug at a temperature of 40-60 ℃; wherein the phase transition temperature of distearoyl phosphatidylcholine is 50-60 ℃, the phase transition temperature of dimyristoyl phosphatidylcholine is 20-30 ℃, the two liposomes are reasonably mixed according to a certain comparison to realize that the phase transition temperature is controlled within 40-60 ℃, and the film fluidity of the thermosensitive liposome is enhanced at the phase transition temperature, so that the medicine is released to an affected part.
The proposal increases cholesterol in the liposome, can improve the rigidity of the liposome, prevent the medicine from cracking when contacting with the heat transfer component, and improve the stability of the medicine in the liposome.
Preferably, the method comprises the following steps of: 20-30 parts of liposome, 1-5 parts of cholesterol, 20-25 parts of electrolyte and 20-25 parts of medicine.
Preferably, the distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine are in a mass ratio of (1-3): 1.
More preferably, the heat transfer component further comprises: polyvinyl alcohol and polyvinylpyrrolidone.
The polyvinyl alcohol adopts medical grade polyvinyl alcohol, has good biocompatibility, and can promote the formation of a film to be stuck on the surface of the skin after being released to the skin, thereby enhancing the bonding effect of the medicine on the skin.
The polyvinylpyrrolidone has physiological inertia, does not irritate skin, mucous membrane and the like, can increase the hydrophilicity and lubricity of the medicine in the polyvinyl alcohol, and ensures that the medicine can move in the polyvinyl alcohol more easily; when polyvinyl alcohol and polyvinylpyrrolidone are used simultaneously, the slow release amount of the medicine can be improved by a small amount.
Further preferably, the heat transfer component comprises the following components in parts by mass: 15-25 parts of polyolefin, 30-45 parts of nano silicon dioxide, 30-45 parts of graphene, 8-10 parts of polyvinyl alcohol and 15-19 parts of polyvinylpyrrolidone.
Preferably, the heat transfer component comprises the following components in parts by mass: 30-45 parts of graphene, 30-45 parts of nano silicon dioxide and 15-25 parts of polyolefin.
Preferably, the heating layer is fitted with an infrared device with adjustable intensity.
The infrared device can emit infrared light, the light emphasis of the infrared light is adjustable, and the function of automatically adjusting the radiation temperature is realized, so that the temperature in the slow release layer is controllable, and the speed of the medicine in the slow release process is controllable. Meanwhile, the infrared device can partially act on subcutaneous tissues, so that blood circulation is promoted, and absorption of medicines at affected parts is accelerated.
More preferably, the heating layer is provided with a transparent medicine groove; the irradiation end of the infrared device irradiates towards the medicine tank.
The medicine groove is used for placing medicine, when the irradiation end of the infrared device irradiates the medicine groove, the medicine groove is transparent and can transmit infrared light, so that the temperature of the slow-release layer is raised to 40-60 ℃; and reduces the temperature of the infrared radiation when the temperature is too high or too low.
Meanwhile, the irradiation ends of the infrared device are multiple and are sequentially arranged, and the irradiation ends intermittently irradiate the slow-release layer.
The slow release layer corresponds to a ring-shaped wearing article and can be worn on the body; the infrared device is provided with the irradiation ends which are arranged in order, so that the irradiation ends can irradiate the middle affected part at different positions; the irradiation end of the scheme is preferably intermittently irradiated on the slow-release layer, such as left-to-right irradiation, the number of the lamps is 3, the lamps are temporarily extinguished after being completely lighted, and thus the cyclic irradiation can prevent the local overheating of the slow-release layer; meanwhile, the number of the irradiation ends is not limited to the horizontal plane when the irradiation ends are sequentially arranged, and the irradiation ends can also be of a ring-shaped structure or an arc-shaped structure.
Example a:
the ratio between the heat transfer component and the effective component is 5:1, a step of;
the heat transfer component comprises the following components in parts by weight: 20 parts of polyolefin, 40 parts of nano silicon dioxide and 40 parts of graphene; the polyolefin is polypropylene;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is aspirin.
Comparative example A1:
the ratio between the heat transfer component and the effective component is 5:1, a step of;
the heat transfer component comprises the following components in parts by weight: 100 parts of polypropylene;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is aspirin.
Comparative example A2:
the ratio between the heat transfer component and the effective component is 5:1, a step of;
the heat transfer component comprises the following components in parts by weight: 40 parts of nano silicon dioxide;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is aspirin.
Comparative example A3:
the ratio between the heat transfer component and the effective component is 5:1, a step of;
the heat transfer component comprises the following components in parts by weight: 40 parts of graphene;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is aspirin.
Blank A4:
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is aspirin.
5g of the heat transfer component in example A and comparative examples A1 to A3 were mixed with 1g of the active component in proportion, respectively; wherein the heat transfer component of blank A4 is 1g; before mixing, vibrating the effective components by ultrasonic until the effective components are uniformly mixed; the prepared slow-release medicine is applied to the skin peeling affected part caused by severe abrasion, and the affected part is repeatedly and intermittently irradiated by infrared light for 15min, wherein the irradiation time is from 8 hours in the morning to 8 hours in the evening;
statistical treatment effect after 7 days; and the diet, the rest and the activities of the patient are strictly controlled in the treatment process; the Chinese medicine and western medicine cannot be eaten, and the physical treatment cannot be accepted; too vigorous activities cannot be performed.
The design makes a standard grade of judgment of treatment effect 7 days later for patients:
3 stages: the clinical symptoms disappear, the pain of the affected part is dissipated, the activity function is recovered, the free activity is realized, and no obstacle is caused.
2 stages: pain at the affected part is relieved, although the pain can not move freely, movement disorder is reduced to slight, and movement function is slightly recovered, so that moderate movement can be performed.
Stage 1: there is no improvement in symptoms or the possibility of exacerbation.
After 7 days, the treatment effect of the patients is shown in table 1, wherein the treatment effect of the patients is effective from level 3 to level 2;
TABLE 1 therapeutic Effect of transdermal drug delivery layer on abrasion
Description:
1. as can be seen from Table 1, the heat transfer component of example A uses polyolefin, nano silicon dioxide and graphene as heat transfer components, and the heat transfer of the effective components is uniform during infrared irradiation, so that the slow release speed of the effective components is ensured to be stable, not to be too high or too low, and the effective components are further ensured to remain during the next infrared irradiation, so that the optimal effective rate of example A is 92%.
2. As can be seen from Table 1, in comparative example A1, only polypropylene is used, the heat transfer effect of polypropylene is low relative to nano silicon dioxide and graphene, and the heat storage is facilitated, but the system lacks materials with better heat conduction, so that the heat is only localized, the temperature of the effective components cannot be well controlled to be 40-60 ℃ as a whole, the treatment effect is not ideal, the effective rate is only 56%, the treatment effect of level 3 is not obvious, and only 1 person. The comparative example A2 only uses nano silicon dioxide, has moderate heat conduction effect, is positioned between polyolefin and graphene, and has better effective rate than the embodiment only using nano silicon dioxide and graphene; in the comparative example A3, only graphene is used, the graphene has good thermal conductivity, and because the graphene has good thermal conductivity, heat is not easy to store, and the effective components can not reach 40-60 ℃ when no infrared irradiation exists, so that the treatment effect is poor, and the effective rate is only 60%.
Example B:
taking 5g of heat transfer component and 1g of active component to be mixed into a slow-release medicine;
the heat transfer component comprises the following components in parts by weight: 20 parts of polyolefin, 40 parts of nano silicon dioxide, 40 parts of graphene, 9 parts of polyvinyl alcohol and 16 parts of polyvinylpyrrolidone;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is NaCl; the medicine is ginkgo extract.
Example C:
taking 0.5g of heat transfer component and 5g of active component, and mixing to obtain a slow-release medicine;
the heat transfer component comprises the following components in parts by weight: 15 parts of polyolefin, 45 parts of nano silicon dioxide and 30 parts of graphene;
the active components comprise the following components in parts by weight: 20 parts of liposome, 5 parts of cholesterol, 20 parts of electrolyte and 25 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is KCl; the medicine is ginkgo extract.
Example D:
taking 10g of heat transfer component and 1g of active component to be mixed into a slow-release medicine;
the heat transfer component comprises the following components in parts by weight: 20 parts of polyolefin, 40 parts of nano silicon dioxide and 40 parts of graphene;
the active components comprise the following components in parts by weight: 25 parts of liposome, 3 parts of cholesterol, 22 parts of electrolyte and 21 parts of medicine; the liposome is distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine; distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine in a mass ratio of 1:1, a step of; the electrolyte is KCl; the medicine is ginkgo extract.
The active components of examples B to D were mixed in proportions, respectively; before mixing, vibrating the effective components by ultrasonic until the effective components are uniformly mixed; the prepared slow-release medicine is applied to the skin peeling affected part caused by severe abrasion, and the affected part is repeatedly and intermittently irradiated by infrared light for 15min, wherein the irradiation time is from 8 hours in the morning to 8 hours in the evening;
statistical treatment effect after 7 days; and the diet, the rest and the activities of the patient are strictly controlled in the treatment process; the Chinese medicine and western medicine cannot be eaten, and the physical treatment cannot be accepted; too vigorous activities cannot be performed.
The design makes a standard grade of judgment of treatment effect 7 days later for patients:
3 stages: the clinical symptoms disappear, the pain of the affected part is dissipated, the activity function is recovered, the free activity is realized, and no obstacle is caused.
2 stages: pain at the affected part is relieved, although the pain can not move freely, movement disorder is reduced to slight, and movement function is slightly recovered, so that moderate movement can be performed.
Stage 1: there is no improvement in symptoms or the possibility of exacerbation.
After 7 days, the treatment effect of the patients is shown in table 2, wherein the treatment effect of the patients is effective from level 3 to level 2;
TABLE 2 therapeutic Effect of transdermal drug delivery layer on abrasion
The technical principle of the present invention is described above in connection with the specific embodiments. The description is made for the purpose of illustrating the general principles of the invention and should not be taken in any way as limiting the scope of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of this specification without undue burden.
Claims (4)
1. Use of a drug delivery layer for the preparation of a transdermal drug delivery, said drug delivery layer comprising, in order: a heating layer and a slow release layer;
the heating layer has a heating function and is used for promoting the slow release layer to slowly release the slow release medicine in a heating state, and the heating temperature is 40-60 ℃; the slow release layer is attached to the affected part of the skin;
the slow release medicine comprises: a heat transfer component and an effective component, wherein the heat transfer component is 5g and the effective component is 1g;
the heat transfer component comprises, by mass, 20 parts of polyolefin, 40 parts of nano silicon dioxide, 40 parts of graphene, 9 parts of polyvinyl alcohol and 16 parts of polyvinylpyrrolidone;
the effective components comprise the following components in parts by weight: distearoyl phosphatidylcholine and dimyristoyl phosphatidylcholine add up to 25 parts, 3 parts cholesterol, 22 parts electrolyte and 21 parts drug; the mass ratio of distearoyl phosphatidylcholine to dimyristoyl phosphatidylcholine is 1:1, a step of; the electrolyte is NaCl; the medicine is ginkgo extract.
2. Use of a drug delivery layer according to claim 1 for the preparation of a transdermal drug delivery, characterized in that the heating layer is provided with an intensity-adjustable infrared device.
3. Use of a drug delivery layer according to claim 2 for the preparation of a transdermal drug delivery, wherein the heating layer is provided with a transparent drug groove; the irradiation end of the infrared device irradiates towards the medicine tank.
4. The use of a drug delivery layer according to claim 2, wherein the infrared device has a plurality of irradiation ends arranged in sequence, and the irradiation ends intermittently irradiate the sustained release layer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110234195.6A CN112999200B (en) | 2021-03-03 | 2021-03-03 | Transdermal drug delivery layer |
| PCT/CN2021/111213 WO2022183679A1 (en) | 2021-03-03 | 2021-08-06 | Transdermal drug delivery layer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110234195.6A CN112999200B (en) | 2021-03-03 | 2021-03-03 | Transdermal drug delivery layer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112999200A CN112999200A (en) | 2021-06-22 |
| CN112999200B true CN112999200B (en) | 2024-04-09 |
Family
ID=76403520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110234195.6A Active CN112999200B (en) | 2021-03-03 | 2021-03-03 | Transdermal drug delivery layer |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112999200B (en) |
| WO (1) | WO2022183679A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999200B (en) * | 2021-03-03 | 2024-04-09 | 北京昊澄生物科技有限公司 | Transdermal drug delivery layer |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332622A (en) * | 1998-09-29 | 2002-01-23 | 扎尔斯公司 | Method and apparatus for improved administration of pharmaceutically active compounds |
| CN1899644A (en) * | 1998-09-29 | 2007-01-24 | 沙斯公司 | Methods and apparatus for improved administration of pharmaceutically active compounds |
| CN101744842A (en) * | 2008-12-01 | 2010-06-23 | 马德林 | Lipidosome Chinese traditional medicine membranous plaster |
| CN103908429A (en) * | 2014-03-27 | 2014-07-09 | 深圳先进技术研究院 | Thermosensitive liposome and preparation method and application thereof |
| CN105111838A (en) * | 2015-08-13 | 2015-12-02 | 蚌埠南自仪表有限公司 | Blended graphene and silicon dioxide dispersing and heat-dispersion paint and preparation method therefor |
| CN105514066A (en) * | 2016-01-19 | 2016-04-20 | 合肥微晶材料科技有限公司 | Composite graphene infrared radiation and heat conduction film and manufacturing method thereof |
| CN105898907A (en) * | 2016-06-12 | 2016-08-24 | 杭州白熊科技有限公司 | Graphene heating film and preparation method thereof |
| CN110511609A (en) * | 2019-09-26 | 2019-11-29 | 威海云山科技有限公司 | Aqueous self limiting temperature fever ink of a kind of graphene and preparation method thereof and the application in heating film |
| CN110559201A (en) * | 2019-08-30 | 2019-12-13 | 上海科颜生物科技有限公司 | Bioactive slow-release composition |
| CN110960694A (en) * | 2019-12-12 | 2020-04-07 | 深圳先进技术研究院 | Indocyanine green liposome for near-infrared two-region fluorescence detection and preparation method and application thereof |
| CN112190576A (en) * | 2020-10-19 | 2021-01-08 | 江苏集萃新型药物制剂技术研究所有限公司 | Composition of skin external preparation, skin external preparation and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10107165A1 (en) * | 2001-02-15 | 2002-08-29 | Max Planck Gesellschaft | Thermolabile liposome with controlled release temperature |
| US20110027331A1 (en) * | 2009-07-29 | 2011-02-03 | Warsaw Orthopedic, Inc. | An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation |
| WO2011019668A1 (en) * | 2009-08-09 | 2011-02-17 | Meltology, Llc | Topical cosmeceutical formulation and methods of making and using same |
| CN101756903A (en) * | 2009-11-27 | 2010-06-30 | 东南大学 | Preparation process of nanometer magnetic drug-carrying gene-carrying thermal controlled release liposome |
| CN102961753B (en) * | 2012-12-06 | 2014-04-23 | 东华大学 | Copper sulfide/mesoporous silicon dioxide core-shell nano material as well as preparation method and application thereof |
| WO2014147073A1 (en) * | 2013-03-21 | 2014-09-25 | Koninklijke Philips N.V. | A system for delivering cosmetic ingredients to the skin |
| CN112999200B (en) * | 2021-03-03 | 2024-04-09 | 北京昊澄生物科技有限公司 | Transdermal drug delivery layer |
-
2021
- 2021-03-03 CN CN202110234195.6A patent/CN112999200B/en active Active
- 2021-08-06 WO PCT/CN2021/111213 patent/WO2022183679A1/en active Application Filing
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332622A (en) * | 1998-09-29 | 2002-01-23 | 扎尔斯公司 | Method and apparatus for improved administration of pharmaceutically active compounds |
| CN1899644A (en) * | 1998-09-29 | 2007-01-24 | 沙斯公司 | Methods and apparatus for improved administration of pharmaceutically active compounds |
| CN101744842A (en) * | 2008-12-01 | 2010-06-23 | 马德林 | Lipidosome Chinese traditional medicine membranous plaster |
| CN103908429A (en) * | 2014-03-27 | 2014-07-09 | 深圳先进技术研究院 | Thermosensitive liposome and preparation method and application thereof |
| CN105111838A (en) * | 2015-08-13 | 2015-12-02 | 蚌埠南自仪表有限公司 | Blended graphene and silicon dioxide dispersing and heat-dispersion paint and preparation method therefor |
| CN105514066A (en) * | 2016-01-19 | 2016-04-20 | 合肥微晶材料科技有限公司 | Composite graphene infrared radiation and heat conduction film and manufacturing method thereof |
| CN105898907A (en) * | 2016-06-12 | 2016-08-24 | 杭州白熊科技有限公司 | Graphene heating film and preparation method thereof |
| CN110559201A (en) * | 2019-08-30 | 2019-12-13 | 上海科颜生物科技有限公司 | Bioactive slow-release composition |
| CN110511609A (en) * | 2019-09-26 | 2019-11-29 | 威海云山科技有限公司 | Aqueous self limiting temperature fever ink of a kind of graphene and preparation method thereof and the application in heating film |
| CN110960694A (en) * | 2019-12-12 | 2020-04-07 | 深圳先进技术研究院 | Indocyanine green liposome for near-infrared two-region fluorescence detection and preparation method and application thereof |
| CN112190576A (en) * | 2020-10-19 | 2021-01-08 | 江苏集萃新型药物制剂技术研究所有限公司 | Composition of skin external preparation, skin external preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 金哲主审."多途径给药促进炎症吸收".《金哲妇科临证思辨》.中国中医药出版社,2020, * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022183679A1 (en) | 2022-09-09 |
| CN112999200A (en) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2452517T3 (en) | Compositions and methods for the treatment of attention deficit disorder and attention deficit hyperactivity disorder with methylphenidate | |
| US6528086B2 (en) | Methods and apparatus for drug delivery involving phase changing formulations | |
| US10010648B2 (en) | Transdermal delivery system | |
| JP2002500180A5 (en) | ||
| CN108578355B (en) | Transdermal drug delivery microneedle system with photothermal effect, and preparation method and application thereof | |
| US20030175354A1 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
| CN112999200B (en) | Transdermal drug delivery layer | |
| CN103990230B (en) | A kind of far-infrared magnet therapeutic healing accelerating dressing and preparation method thereof | |
| CN115737782A (en) | Microneedle patch carrying melittin nanoparticles and/or antigens, preparation method and application | |
| WO2011097081A2 (en) | Methods and compositions for oxygenation of skin to treat skin disorders | |
| Thomas et al. | Hemangiomas of infancy: treatment of ulceration in the head and neck | |
| CN114099936A (en) | Long-acting soluble microneedle for cosmetic filling and sustained-release administration and preparation method thereof | |
| CN204017156U (en) | A kind of far-infrared magnet therapeutic healing accelerating dressing | |
| CN111544757A (en) | Anti-hemangioma drug-loaded microneedle patch and preparation method thereof | |
| NZ239074A (en) | Self-sticking matrix system for sustained transcutaneous release of piribedil | |
| CN211675895U (en) | Antibacterial transdermal drug delivery device | |
| CN204092615U (en) | A kind of pain relieving is applied ointment or plaster | |
| Karatieieva et al. | Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes | |
| CN101336992B (en) | Traditional Chinese medicine preparation for treating early burn or scald | |
| US20040127428A1 (en) | Use of D-ribose, including as a topical vehicle, to promote faster healing, including from surgical procedures | |
| CN111110831A (en) | Ulcer paste and preparation method thereof | |
| RU2586043C1 (en) | Method for prevention and treatment of complications in radiation therapy of skin cancer | |
| CN114209976B (en) | Soluble microneedle photodynamic therapy device | |
| CN110123819B (en) | Medicine and device for treating scars | |
| RU2539418C1 (en) | Method of treating locally advanced oropharyngeal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220129 Address after: 102600 105-213, floor 1, building 24, yard 1, Hongye East Road, Daxing District, Beijing Applicant after: Beijing Haocheng Biotechnology Co.,Ltd. Address before: 510030 room 2902, building C, Dongyue Yaju, 66 Yuexiu Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Applicant before: Zhang Keng |
|
| GR01 | Patent grant |